Indication

Ovarian Cancer

Clinical and regulatory intelligence for Ovarian Cancer with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Assets: 4

Relevant assets

Relevant companies

Bristol-Myers Squibb →

Recent signals(4)

ClinicalJune 21, 2026

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

ClinicalJune 21, 2026

Phase II Trial of M6620 and Gemcitabine in Recurrent Ovarian Cancer

A phase II trial is evaluating the efficacy of ATR kinase inhibitor M6620 combined with gemcitabine hydrochloride in recurrent ovarian cancer.

ClinicalJune 19, 2026

CRLX101 and Paclitaxel Combination Study in Ovarian Cancer Initiated by NewLink Genetics

A clinical trial is underway to evaluate the maximum tolerated dose of CRLX101 in combination with weekly paclitaxel for ovarian cancer patients.

ClinicalJune 17, 2026

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Polyploid giant cancer cells (PGCCs) contribute to therapy resistance and poor prognosis in ovarian cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Oncology →

Ovarian Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.